These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 31096265

  • 1. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
    McCaul ME, Wand GS, Kuwabara H, Dannals RF, Wong D, Xu X.
    Nicotine Tob Res; 2020 May 26; 22(6):892-899. PubMed ID: 31096265
    [Abstract] [Full Text] [Related]

  • 2. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
    Rollema H, Hurst RS.
    Psychopharmacology (Berl); 2018 Sep 26; 235(9):2479-2505. PubMed ID: 29980822
    [Abstract] [Full Text] [Related]

  • 3. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):47-55. PubMed ID: 16820546
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD, Williams KE.
    Neuropharmacology; 2007 Mar 05; 52(3):985-94. PubMed ID: 17157884
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR.
    Clin Ther; 2007 Jun 05; 29(6):1040-56. PubMed ID: 17692720
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Williams KE.
    Clin Ther; 2007 Jun 05; 29(6):1027-39. PubMed ID: 17692719
    [Abstract] [Full Text] [Related]

  • 7. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
    Bordia T, Hrachova M, Chin M, McIntosh JM, Quik M.
    J Pharmacol Exp Ther; 2012 Aug 05; 342(2):327-34. PubMed ID: 22550286
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, Varenicline Phase 3 Study Group.
    JAMA; 2006 Jul 05; 296(1):56-63. PubMed ID: 16820547
    [Abstract] [Full Text] [Related]

  • 9. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
    West R, Baker CL, Cappelleri JC, Bushmakin AG.
    Psychopharmacology (Berl); 2008 Apr 05; 197(3):371-7. PubMed ID: 18084743
    [Abstract] [Full Text] [Related]

  • 10. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S.
    J Cardiovasc Nurs; 2006 Apr 05; 21(6):433-6. PubMed ID: 17293731
    [Abstract] [Full Text] [Related]

  • 11. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
    Rollema H, Shrikhande A, Ward KM, Tingley FD, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D.
    Br J Pharmacol; 2010 May 05; 160(2):334-45. PubMed ID: 20331614
    [Abstract] [Full Text] [Related]

  • 12. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
    Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI.
    Neuropharmacology; 2018 Aug 05; 138():72-79. PubMed ID: 29860196
    [Abstract] [Full Text] [Related]

  • 13. PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics.
    Wong DF, Kuwabara H, Kim J, Brasic JR, Chamroonrat W, Gao Y, Valentine H, Willis W, Mathur A, McCaul ME, Wand G, Gean EG, Dannals RF, Horti AG.
    J Nucl Med; 2013 Aug 05; 54(8):1308-14. PubMed ID: 23801676
    [Abstract] [Full Text] [Related]

  • 14. Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.
    Lesage E, Aronson SE, Sutherland MT, Ross TJ, Salmeron BJ, Stein EA.
    JAMA Psychiatry; 2017 Jun 01; 74(6):632-640. PubMed ID: 28403383
    [Abstract] [Full Text] [Related]

  • 15. Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.
    Hamouda AK, Jackson A, Bagdas D, Imad Damaj M.
    Nicotine Tob Res; 2018 Jun 07; 20(7):903-907. PubMed ID: 29059422
    [Abstract] [Full Text] [Related]

  • 16. Effects of varenicline on smoking cue–triggered neural and craving responses.
    Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR.
    Arch Gen Psychiatry; 2011 May 07; 68(5):516-26. PubMed ID: 21199958
    [Abstract] [Full Text] [Related]

  • 17. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.
    Brody AL, Mandelkern MA, Costello MR, Abrams AL, Scheibal D, Farahi J, London ED, Olmstead RE, Rose JE, Mukhin AG.
    Int J Neuropsychopharmacol; 2009 Apr 07; 12(3):305-16. PubMed ID: 18706128
    [Abstract] [Full Text] [Related]

  • 18. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
    Hussmann GP, DeDominicis KE, Turner JR, Yasuda RP, Klehm J, Forcelli PA, Xiao Y, Richardson JR, Sahibzada N, Wolfe BB, Lindstrom J, Blendy JA, Kellar KJ.
    J Neurochem; 2014 May 07; 129(4):721-31. PubMed ID: 24422997
    [Abstract] [Full Text] [Related]

  • 19. Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia.
    Johnstone S, Sorkhou M, Rabin RA, George TP.
    Drug Alcohol Depend; 2022 May 01; 234():109412. PubMed ID: 35395548
    [Abstract] [Full Text] [Related]

  • 20. A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.
    Lotfipour S, Mandelkern M, Alvarez-Estrada M, Brody AL.
    Neuropsychopharmacology; 2012 Jun 01; 37(7):1738-48. PubMed ID: 22395733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.